media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Its groundbreaking innovative drug, Ruxolitinib Phosphate Cream, has been approved for marketing in China. It is the first and only targeted drug approved in China for the treatment of vitiligo.

Ruxolitinib phosphate cream is the first and only targeted drug approved in China for the treatment of vitiligo, bringing new hope to millions of vitiligo patients in China and marking a significant milestone. Both overseas Phase III clinical trials of the product for the treatment of vitiligo met their primary endpoints: after 24 weeks of treatment, the proportion of patients with F-VASI 75 was 29.9%, significantly higher than the 7.5% and 12.9% in the placebo group. Continued use up to 52 weeks showed sustained repigmentation. Furthermore, real-world studies in China also showed positive efficacy, consistent with the results of pivotal clinical studies abroad; all secondary efficacy endpoints in both domestic and international clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect continued to improve with the extension of treatment duration. This approval will further enrich Demag Pharmaceuticals’ product portfolio and is expected to ...
- Source: drugdu
- 35
- February 3, 2026
Lunan Pharmaceutical’s Bilastin Receives Marketing Approval in Japan

Recently, Shandong New Era Pharmaceutical Co., Ltd., a subsidiary of Lunan Pharmaceutical Group, received a GMP compliance inspection notification from the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan for its product Bilastin (MF registration number: 307MF10026), marking its official acquisition of commercial sales qualification in the Japanese market . This active pharmaceutical ingredient received approval for its marketing application in China in April 2025. It is the sixth MF approved in Japan, following miglitol, montelukast sodium, tegafur, isosorbide, and mosapride citrate. This successful acquisition of market access in Japan provides crucial qualifications for its expansion into the international market. Bilastin is used for the symptomatic treatment of urticaria in adults and adolescents (12 years and older). It is a second-generation non-sedating long-acting histamine antagonist with selective peripheral H1 receptor antagonist affinity, no affinity for muscarinic receptors, no sedative effect, no cardiotoxicity, and does not interact with cytochrome P450 enzyme ...
- Source: drugdu
- 34
- February 3, 2026
Sinovac Biotech expects its net profit to increase by 328.83% to 455.89% in 2025

Sinovac recently released its 2025 annual performance forecast. The company expects its net profit attributable to shareholders to be between RMB 135 million and RMB 175 million in 2025, representing a year-on-year increase of 328.83% to 455.89%. The company stated that this performance growth is the result of its long-term implementation of the “innovation + internationalization” dual strategy. the innovative drug pipeline lay the foundation for revenue growth. According to reports, in 2025, Sinovac Biotech focused on the fields of oncology, autoimmune diseases, and metabolism, actively developing both first-in-class (FIC) and best-in-class (BIC) drugs. Among them, GB18 injection, a drug for treating cancer cachexia, has received clinical trial approvals from the US FDA and the Chinese NMPA, and is currently actively advancing its Phase I clinical trial in China, leading the domestic pipeline for the same target and indication. GB24, focusing on inflammatory bowel disease, is expected to address the ...
- Source: drugdu
- 29
- February 3, 2026
Major approval! The world’s first cAMP-biased GLP-1 inhibitor, Synvita’s “Enoglutide,” has been approved for marketing

Enoglutide Injection (formerly known as Enoglutide, code name XW003), independently developed by Hangzhou Xianweida Biotechnology , for the purpose of glycemic control in adults with type 2 diabetes. This is Syntec’s first commercialized product and the world’s first approved cAMP-biased GLP-1 receptor agonist. of enoglutide is its world-first cAMP-biased mechanism of action, which is the key difference between it and existing GLP-1 products. Traditional GLP-1 products are “unbiased,” and when they activate the beneficial cAMP signaling pathway, they recruit β-arrestin, leading to receptor desensitization and affecting long-term efficacy. In contrast, enoglutide, through precise molecular design, can selectively activate the cAMP pathway and minimize β-arrestin recruitment, maintaining continuous therapeutic signals. Its development is based on the biased activating theory/concept derived from the Nobel Prize-winning GPCR research , which has significant scientific implications. This product is a long-acting weekly formulation, administered via subcutaneous injection, and its activity and production capacity are enhanced ...
- Source: drugdu
- 31
- February 3, 2026
Evidence-based breakthrough! Traditional Chinese medicine for anti-fibrosis selected again for the National Science and Technology Major Project

In the field of liver disease, the long-term damage caused by the vast majority of chronic liver diseases leads to the occurrence and development of liver fibrosis. The degree and rate of progression of liver fibrosis directly affect the risk of cirrhosis and liver cancer. Therefore, effective intervention and reversal of the liver fibrosis process are of vital clinical significance. Unlike other disease treatment areas, traditional Chinese medicine (TCM) has shown unique potential in this field. Recently, Ganxianle® , a modern TCM product under Baiyang Pharmaceuticals , which strengthens the body’s resistance and removes blood stasis, participated in the National Science and Technology Major Project led by Beijing Ditan Hospital affiliated to Capital Medical University—”Research on the Comprehensive Evaluation System and Optimization Scheme of the Whole Chain of Integrated Traditional Chinese and Western Medicine Treatment to Reverse Hepatitis B Cirrhosis”. The selection criteria for the National Science and Technology Major ...
- Source: drugdu
- 29
- February 3, 2026
Amgen terminates development of a Phase 3 clinical antibody drug

recently announced the termination of its collaboration agreement with Japanese pharmaceutical company Kyowa Kirin regarding rocatinlimab, a candidate drug for autoimmune diseases. Five years ago, Amgen paid a $400 million upfront payment and committed to milestone payments of up to $850 million to acquire the global (excluding Japan) rights to develop, manufacture, and commercialize rocatinlimab. According to a press release from Kyowa Kirin, the termination of this agreement was based on Amgen’s strategic priorities regarding its product portfolio . Kyowa Kirin will regain global rights to rocatinlimab. Rocatinlimab (AMG451/KHK4083) is a blocking OX40 antibody with ADCC activity developed by Kyowa Kirin . Previously, rocatinlimab met all co-primary and key secondary endpoints in two Phase 3 clinical trials for atopic dermatitis (AD), ROCKET-IGNITE and ROCKET-HORIZON, including skin clearance rate, which met the requirements for US regulatory filing. In the ROCKET-IGNITE study, 42.3% and 36% of patients receiving 300 mg and 150 ...
- Source: drugdu
- 29
- February 3, 2026
Bio Korea

Organiser：Korea Health Industry Development Institute Time：April 29 – May 1, 2026 Address：513 Yeongdong-daero, Gangnam District, Seoul, South Korea Exhibition hall： COEX Convention & Exhibition Center Product range: Bioprocess Engineering: Bioreactors, bioreactor equipment, bioprocess development, GLP/GMP, bioreactor analysis, aseptic techniques, downstream processing, ultrapure water systems, laboratory equipment, logistics, measurement and control Bioinformatics: Databases, molecular bioinformatics, modeling software/simulation software, chemometrics, bio-evolutionary strategies, drug certification software, data mining, scientific software, laboratory information management systems, laboratory electronic record systems, personal software services, process optimization software, knowledge management, image processing Bioanalysis: Process analysis, biosensors, genomics, proteomics, and other omics, diagnostics, electrophoresis/capillary electrophoresis, biotechnical services, pharmaceuticals, diagnostics, biopharmaceutical applications About Bio Korea ： Bio Korea, established in 2006, is South Korea’s and even Asia’s premier event in the biotechnology industry. The event consists of several parts, including the main conference, business forums, exhibitions, pharmaceutical sub-exhibition areas with special events, medical device sub-exhibition areas with special events, ...
- Source: drugdu
- 30
- February 3, 2026
PotentiaBiotech Supports CSPC Group in Obtaining IND Approval for China’s First In Vivo CAR-T Therapy

On January 29, 2026, PotentiaBiotech supported CSPC Group in obtaining implied approval for clinical trials from the National Medical Products Administration (NMPA) for its independently developed SYS6055 Injection, with the application acceptance number: CXSL2500947. This marks China’s first in vivo CAR-T therapy to receive clinical trial approval, indicated for relapsed/refractory aggressive B-cell lymphoma. PotentiaBiotech extends its warm congratulations on this milestone achievement! Picture 1: From the Wechat Public Account “PotentiaBiotech” About CSPC Group CSPC Holding Group Co., Ltd. was established in 1997. Guided by its long-standing philosophy of “Developing Quality Medicines for China and Benefiting People Worldwide”, the company has sustained double-digit growth in its core operating indicators for many years through innovation-driven development. It has now grown into an international innovation-oriented enterprise with 28,000 employees. Its listed subsidiary on the Hong Kong Stock Exchange (01093.HK) is a constituent stock of the Hang Seng Index, and ranks 19th globally in ...
- Source: drugdu
- 43
- February 2, 2026
Li Auto Frontier Dynamics Secures $200 Million Series B Financing, Cornerstone Ventures Participates as Investor

LimX Dynamics announced the completion of a $200 million Series B financing round, with Cornerstone Capital as a participant. With full-stack technology, we grasp the pivotal capabilities that drive embodied intelligence toward real-world deployment. As we step into 2026, with the strong support of our existing and new shareholders as well as partners, LimX Dynamics will scale up its investment in R&D and market expansion. Grounded in three core competencies: proprietary hardware design and manufacturing, cerebellum foundation models, and the embodied Agentic OS, LimX Dynamics focuses on breakthroughs in the core technology of fusing the “brain and cerebellum” for embodied intelligence. The company advances original innovation in general-purpose humanoid robots and modular base robots, and will further expand its presence in both the Chinese and global markets through product engineering and the development of a supply chain ecosystem. Over the past two months, LimX Dynamics has successively launched two pivotal ...
- Source: drugdu
- 42
- February 2, 2026
Driven by drugs for lowering blood sugar and losing weight, the export value of Chinese Western medicine preparations has reached a record high

China has always been a major exporter of raw pharmaceutical materials, and how to develop the export of Western medicine products towards higher added value has attracted much attention. 　　Chinese medicineData released on January 29 by the China Chamber of Commerce for Health Products Import and Export shows that in 2025, China’s exports of Western medicine preparations amounted to US$8.841 billion, a year-on-year increase of 27.29%. Among them, the export value of preparations accounted for a record high of 15.85% of the total exports of Western medicine products. 　　Furthermore, in 2025, the export value of pharmaceutical preparations accounted for 7.94% of the total export value of pharmaceutical products, showing a significant upward trend. This reflects the continuous upgrading of China’s pharmaceutical industry from upstream intermediates and raw materials to downstream high-value-added fields such as pharmaceutical preparations. 　　In 2025, China’s exports of Western medicine preparations showed a trend ...
- Source: https://finance.eastmoney.com/a/202601303636737935.html
- 37
- February 2, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.